Knight Therapeutics Inc.

OTCPK:KHTR.F Stock Report

Market Cap: US$547.6m

Knight Therapeutics Management

Management criteria checks 4/4

Knight Therapeutics' CEO is Samira Sakhia, appointed in Aug 2016, has a tenure of 9.67 years. total yearly compensation is CA$2.92M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $2.49M. The average tenure of the management team and the board of directors is 4.7 years and 9.7 years respectively.

Key information

Samira Sakhia

Chief executive officer

CA$2.9m

Total compensation

CEO salary percentage22.00%
CEO tenure9.7yrs
CEO ownership0.5%
Management average tenure4.7yrs
Board average tenure9.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Samira Sakhia's remuneration changed compared to Knight Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025CA$3mCA$642k

-CA$5m

Sep 30 2025n/an/a

-CA$3m

Jun 30 2025n/an/a

CA$383k

Mar 31 2025n/an/a

CA$11m

Dec 31 2024CA$3mCA$579k

CA$4m

Sep 30 2024n/an/a

-CA$31m

Jun 30 2024n/an/a

-CA$21m

Mar 31 2024n/an/a

-CA$17m

Dec 31 2023CA$1mCA$514k

-CA$17m

Sep 30 2023n/an/a

-CA$8m

Jun 30 2023n/an/a

-CA$16m

Mar 31 2023n/an/a

-CA$15m

Dec 31 2022CA$1mCA$468k

-CA$30m

Sep 30 2022n/an/a

-CA$23m

Jun 30 2022n/an/a

-CA$33m

Mar 31 2022n/an/a

-CA$7m

Dec 31 2021CA$1mCA$401k

CA$16m

Sep 30 2021n/an/a

CA$32m

Jun 30 2021n/an/a

CA$59m

Mar 31 2021n/an/a

CA$47m

Dec 31 2020CA$688kCA$298k

CA$42m

Sep 30 2020n/an/a

CA$27m

Jun 30 2020n/an/a

CA$6m

Mar 31 2020n/an/a

CA$8m

Dec 31 2019CA$987kCA$287k

CA$15m

Compensation vs Market: Samira's total compensation ($USD2.13M) is about average for companies of similar size in the US market ($USD2.39M).

Compensation vs Earnings: Samira's compensation has been consistent with company performance over the past year.

CEO

Samira Sakhia (57 yo)

9.7yrs
Tenure
CA$2,918,243
Compensation

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Goodman
Executive Chairman13.3yrsCA$1.08m22.28%
$ 122.0m
Samira Sakhia
President9.7yrsCA$2.92m0.46%
$ 2.5m
Arvind Utchanah
Chief Financial Officer6.1yrsCA$1.78m0.11%
$ 607.1k
Leopoldo Bosano
Vice-President of Manufacturing & Operations4.1yrsCA$636.90kno data
Susan Emblem
Global Vice President of Human Resources4.7yrsCA$638.91k0.045%
$ 247.8k
Amal Khouri
Chief Business Officer5.1yrsCA$1.72m0.20%
$ 1.1m
Christine Poulin
General Manager of Canadano dataCA$883.72kno data
Monica Percario
Global Vice President of Regulatory & Quality4.7yrsCA$571.09kno data
Henrique Dias
Global Vice President of Marketing4.3yrsCA$599.30k0.012%
$ 67.8k
Melanie Groleau
Global Vice President of Medical & Clinical2.3yrsno data0.011%
$ 58.0k
4.7yrs
Average Tenure

Experienced Management: KHTR.F's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Goodman
Executive Chairman13.3yrsCA$1.08m22.28%
$ 122.0m
Samira Sakhia
President9.7yrsCA$2.92m0.46%
$ 2.5m
James Gale
Independent Lead Director13.3yrsCA$164.12k0.054%
$ 296.0k
Robert Lande
Independent Director12.3yrsCA$140.74k0.25%
$ 1.4m
Nicolas Sujoy
Independent Director5.8yrsCA$149.74k0.012%
$ 65.9k
Janice Murray
Independent Director5.8yrsCA$135.74k0.0092%
$ 50.1k
Michael Tremblay
Independent Director6.9yrsCA$128.24k0.0020%
$ 11.2k
9.7yrs
Average Tenure
58yo
Average Age

Experienced Board: KHTR.F's board of directors are considered experienced (9.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 11:51
End of Day Share Price 2026/04/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Knight Therapeutics Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)
David KideckelBeacon Securities Limited
David MartinBloom Burton & Co.